During the corresponding time, Schrodinger Inc recorded a revenue increase by 7.54 % year on year, sequentially revenue grew by 0.52 %. While revenue at the Schrodinger Inc 's corporate clients
Schrodinger Inc's Comment on Sales, Marketing and Customers
The company provides software solutions for molecule discovery, design, and optimization, serving all of the top 20 pharmaceutical companies by 2024 revenue. These clients accounted for significant portions of the company's software revenue and annual contract value in 2025. Its commercial customers include entities purchasing computational software solutions for commercial use, excluding government and academic institutions. The company also operates the Schrödinger Therapeutics Group, which collaborates with biopharmaceutical companies on drug discovery programs across therapeutic areas such as oncology, antifungal diseases, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immuno-oncology, cardiopulmonary disease, CNS diseases, and tuberculosis. These collaborations typically involve access to the platform and experts, with agreements that include upfront payments, milestones, and royalties.
: Schrodinger, a prominent leader in the field of computational drug discovery, has announced its participation in multiple investor conferences scheduled for March 2025. This engagement presents an opportunity for the company to discuss its groundbreaking developments in pharmaceutical sciences and computational chemistry with investors and industry stakeholders.Advancements in pharmaceutical science and technology are critical for the future of drug development and patient care. Schrodinger (Nasdaq: SDGR) stands at the forefront of this evolution, leveraging cutting-edge computational tools to streamline the discovery process of new therapeutics. In this context, the company recently announced it will part...
Schrodinger Inc’s Comment on Sales, Marketing and Customers
The company provides software solutions for molecule discovery, design, and optimization, serving all of the top 20 pharmaceutical companies by 2024 revenue. These clients accounted for significant portions of the company's software revenue and annual contract value in 2025. Its commercial customers include entities purchasing computational software solutions for commercial use, excluding government and academic institutions. The company also operates the Schrödinger Therapeutics Group, which collaborates with biopharmaceutical companies on drug discovery programs across therapeutic areas such as oncology, antifungal diseases, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immuno-oncology, cardiopulmonary disease, CNS diseases, and tuberculosis. These collaborations typically involve access to the platform and experts, with agreements that include upfront payments, milestones, and royalties.
Sources:
Schrodinger Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Schrodinger Inc’s corporate clients.
For your research, we’ve provided 9 tables on Schrodinger Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
115.65 %